

AD_____

Award Number: DAMD17-01-1-0049

TITLE: Development of Immortalized and Tumorigenic Prostate Cell
Lines of Defined Genetic Constitution

PRINCIPAL INVESTIGATOR: William C. Hahn, M.D., Ph.D.

CONTRACTING ORGANIZATION: Dana-Farber Cancer Institute
Boston, Massachusetts 02115-6084

REPORT DATE: May 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20021101 056

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2002	3. REPORT TYPE AND DATES COVERED Annual (15 Apr 01 - 14 Apr 02)	
4. TITLE AND SUBTITLE Development of Immortalized and Tumorigenic Prostate Cell Lines of Defined Genetic Constitution			5. FUNDING NUMBERS DAMD17-01-1-0049	
6. AUTHOR(S) William C. Hahn, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dana-Farber Cancer Institute Boston, Massachusetts 02115-6084 E-Mail: William_Hahn@dfci.harvard.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) In order to develop a better understanding of the molecular events that transform normal human prostate cells into prostate cancer, we have developed a system of cell transformation that permits the creation of immortalized and tumorigenic human prostate epithelial cell lines of defined genetic constitution. Expression of SV40 Large T antigen and hTERT, the catalytic subunit of telomerase, permitted immortalization. Transformation as assessed by the ability of these cells to form colonies in an anchorage independent fashion and to form tumors in immunodeficient host animals required the additional expression of an oncogenic version of the H-Ras protein. In addition, using hTERT alone, we have simultaneously created an immortalized human prostate stromal cell line. These cell lines provide an important foundation for future studies that will allow us to investigate the precise molecular interactions that lead to the development of prostate cancer. Ultimately, the elucidation of these critical molecular determinants of prostate cancer will permit the identification and confirmation of important targets for future therapeutic intervention.				
14. SUBJECT TERMS Immortalization, transformation, telomerase, prostate epithelial				15. NUMBER OF PAGES 11
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusions.....	9
References.....	10
Appendices.....	11

INTRODUCTION

Development of immortalized and tumorigenic prostate cell lines of defined genetic constitution

The study of prostate cancer cells derived from patients has elucidated many fundamental principles of malignant transformation and permitted the identification of several promising therapeutic targets. However, the critical changes that initiate cancer have been difficult to define with this approach. Currently efforts to understand the pathogenesis of prostate cancer are often limited by the difficulty in maintaining and propagating normal and malignant prostate epithelial cells (PrEC) *ex-vivo* as well as by disease and genetic heterogeneity. Specifically, the study of cancer cells derived from patients does not permit one to study the role of particular genes in the stepwise malignant conversion of normal PrEC to cancer cells in a defined genetic background. To address this need, we have developed a system of cell transformation that permits the creation of immortalized and tumorigenic human prostate epithelial cell lines of defined genetic constitution. Using these systems to define these molecular interactions that lead to the final phenotype of cancer will permit us to expand our understanding of prostate cancer and will identify important targets for therapeutic intervention.

BODY

Task 1. Determine which genetic events cooperate with telomerase expression to immortalize prostate epithelial cells

Telomere maintenance by the activation of the reverse transcriptase telomerase leads to immortalization of several types of human cells including fibroblasts, endothelial cells, and




Figure 1. Expression of hTERT in prostate epithelial and stromal cells. hTERT was introduced by retroviral-mediated gene transfer. Telomerase activity determined by the PCR-based TRAP assay. HT refers to heat-treated control.




Figure 2. Growth of prostate epithelial and stromal cells after introduction of hTERT.

In ongoing studies in keratinocytes, mammary epithelial, and airway epithelial cells, we have




Figure 3. Expression of LT, H-Ras, and ST in PrEC. Antibodies used for detection included Pab101 (LT), C20 (H-Ras), and Pab 419 and Pab 108 (ST).

determined that ablation of the retinoblastoma (pRB) and p53 tumor suppressor pathways cooperates with activation of telomerase to immortalize these types of cells (3-5, 7). In order to determine whether PrEC share similar requirements for immortalization, we introduced the SV40 Early Region containing the SV40 large and small T antigens (LT, ST) into PrEC. SV40 LT binds to and inactivates both the pRB and p53 tumor suppressor proteins and together with hTERT expression immortalizes human mammary epithelial and airway epithelial cells (5, 8). After infection, such cells displayed readily detectable expression of LT (Fig. 3). The co-expression of LT and hTERT also permitted

immortalization of human PrEC (Fig. 4). Immunohistochemical characterization of these immortalized PrEC indicate that they express cytokeratins 5 and 14 and p63 (9) and lack expression of the androgen receptor and PSA, indicating that these PrEC retain a basal phenotype. Thus, we have succeeded in immortalizing both PrEC and prostate stromal cells, a major goal of Task 1.




Figure 4. Proliferation of PrEC in vitro. PrEC expressing control vector (circles), hTERT (squares) or LT + hTERT (triangles).

Task 2. Determine which further events are required to convert immortalized cells into tumorigenic cells.

We previously demonstrated that co-expression of SV40 Early Region, hTERT, and *ras* suffices to convert primary human fibroblasts, HEK, mammary epithelial, and small airway epithelial cells to tumorigenicity (5, 8, 10-12). In order to make a genetically defined model of prostate cancer, we wished to determine what further genetic events are required to convert immortalized PrEC into tumorigenic prostate cells. Although the final goal of these experiments is to create an experimental model of prostate cancer that uses genes known to be mutated in human prostate cancer, we have pursued a stepwise strategy to first establish that PrEC are susceptible to this type of *in vitro* transformation assay and then to refine this model through sequential iterations.

Starting with the immortalized PrEC described in Task 1, we introduced an oncogenic allele of the H-*ras* oncogene (V12). Immunoblotting with a pan-Ras antibody revealed that H-Ras was expressed in these cells. We and others have recently determined that in addition to LT, hTERT, and H-Ras, the SV40 ST oncoprotein was required for transformation in human fibroblasts and kidney epithelial cells (7, 12). Since we used the same retroviral vector that was used in these studies in fibroblasts and kidney epithelial cells to introduce the SV40 Early Region into these immortalized PrEC, we expected and confirmed that these cells also expressed ST (Fig. 3). The proliferation rate of these cells did not differ significantly from the immortalized PrEC when cultured on plastic tissue culture plates (data not shown).

However, when we tested these PrEC expressing LT, ST, hTERT, and H-Ras for their ability to grow in an anchorage-independent fashion, we found that these cells were now able to form colonies in soft agar. Control immortalized PrEC produced in parallel but lacking H-Ras failed to form colonies in soft agar. Correlating with these observations, when we introduced these cells into immunodeficient animal hosts, only PrEC expressing LT, ST, hTERT, and H-Ras were able to form tumors in mice (Table 1). These studies confirm that the additional introduction of H-Ras into immortalized PrEC suffices to confer tumorigenic potential to these cells.

Table 1 Anchorage-independent and tumorigenic growth of PrEC

	Colonies in soft agar	Tumors in animals
PrEC LT + ST + hTERT + vector	-	-
PrEC LT + ST + hTERT + H-Ras	+++	+++

Task 3 Analyze immortalized and tumorigenic prostate epithelial and stromal cells *in vivo* to dissect critical stromal-epithelial interactions

Experiments will commence on this task in the coming year as specified in the original Statement of Work.

KEY RESEARCH ACCOMPLISHMENTS

1. Creation of an immortalized prostate stromal cell line
2. Creation and initial characterization of an immortalized PrEC line
3. Establishment of a system to achieve the transformation of PrEC using sequential gene transfer

REPORTABLE OUTCOMES

1. Development of an immortalized prostate stromal cell line
2. Development of an immortalized PrEC line
3. Development of an immortalized and transformed PrEC line

CONCLUSIONS

In the first year of this award, we have accomplished several of the specific priorities detailed in Statement of Work (Task 1 and Task 2). The creation of these human prostate stromal and epithelial cell lines provide an essential foundation for future studies and represent important reagents for investigators working on prostate epithelial biology. Indeed, these cell lines have already been provided to several other investigators for related but complementary studies.

Although these cell lines represent a significant advance, they are not yet truly representative of spontaneously arising prostate cancer. Furthermore, they retain a basal epithelial cell phenotype. To address these concerns, current and future work will further characterize the biological and phenotypic behavior of these cell lines. In addition, we will now focus on the development of improved prostate cancer cell models that incorporate genetic alterations found associated with spontaneously arising prostate cancer. As detailed in the original proposal and Statement of Work, we will begin by substituting specific dominantly interfering mutants of the pRB and p53 pathways to determine the role of these pathways in immortalization and transformation. In addition, we will begin to develop retroviral libraries derived from prostate cancer cell lines for use in functional screens for genes that are able to substitute for H-Ras expression in this system of transformation. Finally, with the development of an immortalized prostate stromal cell line, we can now begin the experiments outlined in Task 3, which may permit us to generate cell lines that exhibit a luminal phenotype rather than a basal phenotype and which will permit us to study epithelial-stromal interactions during cell transformation.

REFERENCES

1. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. *Science*, 279: 349-352, 1998.
2. Yang, J., Chang, E., Cherry, A. M., Bangs, C. D., Oei, Y., Bodnar, A., Bronstein, A., Chiu, C. P., and Herron, G. S. Human endothelial cell life extension by telomerase expression. *J. Biol. Chem.*, 274: 26141-26148, 1999.
3. Dickson, M. A., Hahn, W. C., Ino, Y., Ronfard, V., Wu, J. Y., Louis, D. N., Weinberg, R. A., Li, F. P., and Rheinwald, J. G. Human keratinocytes that express hTERT and also evade a p16ink4a-enforced lifespan limit become immortal while retaining normal growth and differentiation characteristics. *Mol. Cell. Biol.*, 20: 1436-1447, 2000.
4. Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., and Klingelhutz, A. J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. *Nature*, 396: 84-88, 1998.
5. Lundberg, A. S., Randell, S. H., Stewart, S. A., Elenbaas, B., Hartwell, K. A., Brooks, M. W., Fleming, M. D., Olsen, J. C., Miller, S. W., Weinberg, R. A., and Hahn, W. C. immortalization and transformation of primary human airway epithelial cells by gene transfer. In press, 2002.
6. Kim, N. W. and Wu, F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). *Nucleic Acids Res.*, 25: 2595-2597, 1997.
7. Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., and Weinberg, R. A. Enumeration of SV40 elements necessary for human cell transformation. *Mol Biol Cell*, 22: 2111-2123, 2002.
8. Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., and Weinberg, R. A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. *Genes Dev*, 15: 50-65, 2001.
9. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., and McKeon, F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature*, 398: 714-718, 1999.
10. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. Creation of human tumor cells with defined genetic elements. *Nature*, 400: 464-468, 1999.
11. Rich, J. N., Guo, C., McLendon, R. E., Bigner, D. D., Wang, X. F., and Counter, C. M. A genetically tractable model of human glioma formation. *Cancer Res*, 61: 3556-3560., 2001.
12. Yu, J., Boyapati, A., and Rundell, K. Critical role for SV40 small-t antigen in human cell transformation. *Virology*, 290: 192-198, 2001.

APPENDICES

None